PRGS&Tech's candidate treatment for Neurofibromatosis Type II (NF2), 'Trineumin,' has been finally selected for the "2026 Scaling Up TIPS Policy Designation Project."


PRGS&Tech Finally Selected for "Scaling Up TIPS Policy Designation Project" View original image

According to PRGS&Tech on August 6, the company has secured a total of 3 billion won in government research and development (R&D) grants over the next three years by being selected for this project. Building on this support, the company plans to secure essential data needed to advance Trineumin into Phase 2 clinical trials, and accelerate strategies for global regulatory approval and commercialization.


The Scaling Up TIPS Policy Designation Project is a pan-ministerial R&D program designed to support technology innovation and growth for promising small and venture companies in the biohealth sector. The Ministry of Health and Welfare identifies and recommends biohealth companies with high growth potential, while the Ministry of SMEs and Startups verifies their technological competency and business viability, connecting them with R&D support.


Trineumin is the world's first innovative small-molecule drug candidate that directly targets the pathological mechanism of NF2. It is designed to inhibit the development and progression of tumors by modulating the abnormal interaction between TβR1 and RKIP proteins caused by NF2 gene mutations.


PRGS&Tech received domestic Phase 1/2 clinical trial (IND) approval in 2024, followed by approval of an IND from the U.S. Food and Drug Administration (FDA) in 2025. The company has also been granted the U.S. FDA's Orphan Drug Designation (ODD) and Fast Track, as well as Orphan Medicinal Product Designation (OMPD) from the European Medicines Agency (EMA), receiving recognition for its global development competitiveness.


Currently, Trineumin has completed a Phase 1 maximum tolerated dose and safety evaluation and is conducting additional dose-escalation studies to determine the recommended Phase 2 dose (RP2D). The company plans to accelerate R&D for entry into Phase 2 clinical trials based on this project support.



Bumjun Park, CEO of PRGS&Tech, stated, "This selection for Scaling Up TIPS is significant as it represents official recognition of Trineumin's technological strengths and global commercialization potential." He added, "With the backing of government R&D support and private investment, we will proceed with our Phase 2 clinical trial entry and global regulatory strategies without setbacks."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing